VC firms
Logos Capital
Edit

Logos Capital

https://www.logoscapital.com
Last activity: 10.08.2026
Active
Invests in categories: BioTechDrugHealthTechDevelopmentPlatformMedTechTechnologyResearchProductOncology
Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Email
Portfolio
61
Persons
9
Mentions
27

Overview

Employees
1-10
Investment Stage
Series B

Portfolio 61

DateNameWebsiteTotal RaisedLocation
Sign up to seeSign up to seeSign up to seeSign up to seeSign up to see
Jan 13, 2026Mirador Therapeuticsmiradortx.com$250MUnited States
Nov 16, 2025Beacon Biosignalsbeacon.bio$113MUnited States
Aug 7, 2023Gracell Biotechnologiesgracellbio.com$250MChina, Jiangsu, Suzhou City
Jul 11, 2023@Septerna_Incsepterna.com$290MUnited States, California, South San Francisco
Oct 17, 2022Odyssey Therapeuticsodysseytx.com$487MUnited States, Massachusetts, Cambridge
Aug 27, 2021Willowonewillow.com
Aug 17, 2021Nuvalentnuvalent.com$187.23MUnited States, Massachusetts, Cambridge
Aug 17, 2021Ventyx Biosciencesventyxbio.com$165MUnited States, California, Encinitas
Aug 17, 2021Graphite Biographitebio.com$195.75MUnited States, California, South San Francisco
Show more

Persons 9

DateFirst NameLast NameTitleLinkedInLocation
Sign up to seeSign up to seeSign up to seeSign up to seeSign up to seeSign up to see
BonnyChenSr. Lead, Marketing and Operations
Dr.Graham Walmsley, MD, PhDGeneral Partner
UditDalalVP, Operations
ElanaSearsHead of Marketing and Investor Relations
Dr.Yuqi Wang, PhDAnalyst
Dr.Ed Zhong, PhDGeneral Partner
DerekGould, JDGeneral Counsel / Chief Compliance Officer
Dr.Arsani William, MD, MBAManaging Partner / Chief Investment Officer

Mentions in press and media 27

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Aug 9, 2026Expedition Therapeutics Lands $115M Series B SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic...
Mar 30, 2026Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI PowerPinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab...
Mar 29, 2026Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics DevelopmentPinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F...
Feb 23, 2026Sensei Biotherapeutics Acquires Faeth Therapeutics And Raises $200 Million In Private PlacementSensei Biotherapeutics announced it has acquired Faeth Therapeutics and secured approximately $200 million in gross proceeds through a concurrent private placement, positioning the combined company to advance its oncology pipeline through k...
Jan 14, 2026Mirador Therapeutics Secures $250M, Accelerates Precision MedicineMirador Therapeutics secured $250M in Series B funding. This propels their innovative precision medicine strategy. Total capital raised now exceeds $650M. The San Diego firm targets immune-mediated inflammatory and fibrotic diseases. Funds ...
Jan 13, 2026Mirador Raises $250M in Series B FundingMirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding. Backers included T. Rowe Price Investme...
Jan 11, 2026Diagonal Therapeutics Secures $125M to Propel Innovative Antibody TherapiesDiagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre...
Jan 11, 2026Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the ClinicDiagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i...
Jan 9, 2026Diagonal Therapeutics Raises $125M in Series B FinancingDiagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding. The round was co-led by ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Logos Capital

How many startups has Logos Capital invested in?

Logos Capital has 61 portfolio companies on Parsers VC, among them Mirador Therapeutics, Beacon Biosignals and Gracell Biotechnologies.

What has the press written about Logos Capital?

Parsers VC has collected 27 articles mentioning Logos Capital, among them “Expedition Therapeutics Lands $115M Series B” (Aug 9, 2026) and “Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power” (Mar 30, 2026).

Is Logos Capital still active?

Yes, Logos Capital is active; its latest activity on Parsers VC dates from Aug 10, 2026.